D. Roger Illingworth, MD, PhD

• Degrees:
  M.D.: University of Miami School of Medicine, 1976; Ph.D.: University of Liverpool
• Residency:
  Internal Medicine - Oregon Health & Science University, Portland
• Fellowship:
  Clinical Nutrition/Lipid Metabolism-Oregon Health & Science University, Portland

• Biosketch:
  Dr. Illingworth specializes in lipid disorders and metabolism. He currently serves as a member of a panel of experts in the detection and treatment of hypercholesterolemia. He received his Ph.D. in 1970 from the University of Liverpool in England. In 1976, he earned his medical degree from the University of Miami School of Medicine. Dr. Illingworth completed his residency in Internal Medicine and his fellowship in Clinical Nutrition/Lipid Metabolism at OHSU.
• Recent Publications:
  

  Illingworth DR. Achievement of low-density lipoprotein cholesterol goals: new strategies to address new guidelines. Cardiol Clin. 2003 Aug;21(3):363-75.

  Pappu AS, Bacon SP, Illingworth DR. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia. J Lab Clin Med. 2003 Apr;141(4):250-6.

  Pappu AS, Steiner RD, Connor SL, Flavell DP, Lin DS, Hatcher L, Illingworth DR, Connor WE. Feedback inhibition of the cholesterol biosynthetic pathway in patients with Smith-Lemli-Opitz syndrome as demonstrated by urinary mevalonate excretion. J Lipid Res. 2002 Oct;43(10):1661-9.

  Pappu AS, Illingworth DR. The effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002 Nov;165(1):137-44.

  Knopp RH, Illingworth DR, Stein EA, Ginsberg HN, Broyles FE, Behounek BD. Effect of Pravastatin in the Treatment of Patients with Type III Hyperlipoproteinemia. Am J Ther. 1996 Nov;3(11):755-762.

• All Publications

This site last updated 1/6/04.
Send your comments about the site to the Web Manager.